Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Auna S.A. operates a network of private hospitals, clinics, and oncology centers across Peru, Colombia, and Mexico, serving middle-to-upper income patients seeking quality healthcare services. The company generates $4.1B in revenue through a vertically integrated model combining hospital infrastructure, specialized oncology treatment (Oncosalud brand), and health insurance products. Stock performance is driven by patient volume trends, payor mix (private insurance vs. out-of-pocket), and Latin American currency fluctuations against the USD.
Auna operates a vertically integrated healthcare platform that captures value across the care continuum. Revenue comes from fee-for-service hospital admissions, outpatient procedures, and specialized oncology treatments billed to private insurers, employer-sponsored plans, and direct-pay patients. The company benefits from limited competition in premium private healthcare segments across its Latin American markets, allowing pricing power with affluent patient populations. Gross margins of 37.9% reflect labor-intensive service delivery and medical supply costs, while operating leverage comes from spreading fixed facility costs across higher patient volumes.
Same-facility patient volume growth and bed occupancy rates across Peru, Colombia, and Mexico hospital networks
Payor mix shifts between higher-margin private insurance patients versus lower-margin out-of-pocket or government reimbursement
Oncosalud membership growth and treatment volumes as cancer care demand increases in Latin America
Latin American currency movements (Peruvian Sol, Colombian Peso, Mexican Peso) affecting USD-reported revenues and debt service costs
Regulatory changes to healthcare reimbursement policies or private insurance mandates in operating countries
Government healthcare policy shifts toward expanded public coverage or price controls on private services could compress margins and limit pricing power in Peru, Colombia, or Mexico
Currency devaluation risk across Latin American operating markets creates translation losses and increases USD debt burden relative to local currency revenues
Physician talent retention challenges as medical professionals emigrate from Latin America to higher-paying developed markets
Entry of international hospital chains (HCA, Fresenius) or regional competitors expanding into premium private healthcare segments
Telemedicine and outpatient clinic models reducing demand for traditional hospital infrastructure and inpatient stays
Consolidation among health insurers increasing their negotiating leverage over reimbursement rates
Elevated 2.28x debt/equity ratio with only 1.11x current ratio creates refinancing risk and limited financial flexibility for growth investments
Negative revenue growth (-6.1% YoY) combined with declining margins suggests operational stress that could pressure debt covenants
Currency mismatch if debt is USD-denominated while revenues are in depreciating Latin American currencies
moderate - Healthcare demand is relatively inelastic for acute and oncology services, but elective procedures and premium service utilization correlate with middle-class income levels in Latin America. Economic downturns can shift payor mix toward lower-margin segments or delay non-urgent treatments. GDP growth in Peru, Colombia, and Mexico directly impacts the target demographic's ability to afford private healthcare versus public alternatives.
High interest rate sensitivity due to 2.28x debt/equity ratio and likely USD-denominated debt servicing costs. Rising US rates increase financing costs and pressure cash flows, particularly problematic given 2.2% net margins. Higher rates also strengthen USD against Latin American currencies, increasing real debt burden. Valuation multiples compress as discount rates rise, though healthcare typically trades at premium to market given defensive characteristics.
Moderate credit exposure through two channels: (1) ability of private insurers and employer health plans to maintain reimbursement rates during credit stress, and (2) company's own refinancing risk given elevated leverage. Tightening credit conditions in Latin American markets could reduce healthcare spending by corporate clients and pressure collection cycles.
value - Trading at 0.3x sales, 0.3x book, and 5.7x EV/EBITDA with 42.7% FCF yield suggests deep value opportunity for investors betting on operational turnaround. Negative recent returns (-28.5% 1-year) and declining fundamentals have created distressed valuation, attracting contrarian value investors and emerging market specialists willing to accept Latin American political/currency risk for potential mean reversion.
high - Small $0.4B market cap with concentrated exposure to volatile Latin American economies and currencies creates significant price volatility. Emerging market healthcare stocks typically exhibit beta >1.2 to broader markets, amplified by company-specific operational challenges evidenced by negative growth rates and thin 2.2% net margins.
